Simulations Plus (SLP) Reaches New 12-Month High and Low at $17.55

Simulations Plus (NASDAQ:SLP)’s share price reached a new 52-week high and low on Wednesday . The company traded as low as $17.55 and last traded at $17.50, with a volume of 39677 shares. The stock had previously closed at $17.35.

A number of research firms have weighed in on SLP. BidaskClub raised Simulations Plus from a “sell” rating to a “hold” rating in a research report on Saturday, April 7th. ValuEngine raised Simulations Plus from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Finally, Zacks Investment Research raised Simulations Plus from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Thursday, March 22nd.

How to Become a New Pot Stock Millionaire

The stock has a market capitalization of $295.41, a price-to-earnings ratio of 51.79 and a beta of -0.56.



Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Monday, April 9th. The technology company reported $0.11 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.11. Simulations Plus had a return on equity of 26.19% and a net margin of 30.65%. The firm had revenue of $7.36 million during the quarter, compared to the consensus estimate of $7.37 million. equities analysts anticipate that Simulations Plus will post 0.4 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 2nd. Stockholders of record on Wednesday, April 25th will be issued a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 1.36%. The ex-dividend date of this dividend is Tuesday, April 24th. Simulations Plus’s payout ratio is presently 70.59%.

In other news, Chairman Walter S. Woltosz sold 18,500 shares of the stock in a transaction that occurred on Tuesday, March 27th. The stock was sold at an average price of $14.54, for a total value of $268,990.00. Following the completion of the sale, the chairman now owns 5,466,408 shares of the company’s stock, valued at approximately $79,481,572.32. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 33.45% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can acquired a new stake in shares of Simulations Plus in the 4th quarter valued at approximately $104,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Simulations Plus by 13.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 8,923 shares of the technology company’s stock valued at $110,000 after buying an additional 1,085 shares during the last quarter. Strs Ohio boosted its holdings in shares of Simulations Plus by 196.9% in the 4th quarter. Strs Ohio now owns 9,500 shares of the technology company’s stock valued at $152,000 after buying an additional 6,300 shares during the last quarter. Algert Global LLC acquired a new stake in shares of Simulations Plus in the 4th quarter valued at approximately $175,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of Simulations Plus by 234.1% in the 4th quarter. Wells Fargo & Company MN now owns 17,028 shares of the technology company’s stock valued at $275,000 after buying an additional 11,931 shares during the last quarter. 33.78% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Simulations Plus (SLP) Reaches New 12-Month High and Low at $17.55” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://stocknewstimes.com/2018/04/18/simulations-plus-slp-reaches-new-12-month-high-and-low-at-17-55.html.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply